Discussion highlights the dual nature of AI's impact in biotech, suggesting both challenges and opportunities.
As someone who sat on the National Academies' study committee on AI and Biosecurity, I can tell you: the truth is neither so dire nor so utopian.
No takes yet. Share an insight, caveat, or question.
Alexander Titus (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: